Acer Therapeutics Inc
ACER
ACER was delisted on the 8th of November, 2023.
37 hedge funds and large institutions have $9.6M invested in Acer Therapeutics Inc in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 15 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
20% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 15
9% more funds holding
Funds holding: 34 → 37 (+3)
87% less capital invested
Capital invested by funds: $76.2M → $9.6M (-$66.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.94M |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$2.12M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.02M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.92M |
| 5 |
JGC
J. Goldman & Co
New York
|
+$1.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$14.1M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$9.42M |
| 3 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$5.35M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$3.57M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$3.04M |
ACER Hedge Fund Activity: Q2 2019 in Review
37 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Acer Therapeutics Inc (ACER) for Q2 2019, worth a combined $9.6M — down 87% from $76.2M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ACER positions and 15 closed out — a net gain of 3 holders — while 11 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, adding an estimated $5.94M. The largest seller was Vivo Capital, exiting entirely with an estimated $14.1M sold.
- 37 institutional investors held Acer Therapeutics Inc (ACER) as of Q2 2019, up from 34 in Q1 2019.
- Funds reported $9.6M of Acer Therapeutics Inc stock for Q2 2019, down 87% quarter-over-quarter.
- 18 funds opened new Acer Therapeutics Inc positions in Q2 2019 and 15 closed out, a net change of +3 holders.
- The largest Acer Therapeutics Inc buyer in Q2 2019 was BlackRock, an estimated $5.94M added.
- The largest Acer Therapeutics Inc seller in Q2 2019 was Vivo Capital, an estimated $14.1M sold.
Based on aggregated 13F filings for Q2 2019.